Aspirin and ovarian cancer: An italian case-control study

A. Tavani, S. Gallus, C. La Vecchia, E. Conti, M. Montella, S. Franceschi

Research output: Contribution to journalArticlepeer-review


Background: A role for inflammation, and consequently of non-steroideal anti-inflammatory drugs, in ovarian carcinogenesis has been proposed, but epidemiological evidence is scanty. Patients and methods: Data were derived from a hospital-based case-control study conducted in Italy between 1992 and 1999. Cases were 749 women, aged 18-80 years (median age 56 years), with incident, histologically confirmed ovarian cancer. Controls were 898 non-hysterectomized women, aged 17-80 years (median age 58 years), admitted to hospital for acute conditions, unrelated to risk factors for ovarian cancer. Results: The multivariate odds ratio (OR) was 0.93 (95% confidence interval (95% CI): 0.53-1.62) for regular aspirin use for more than six months, 1.38 (95% CI: 0.57-3.36) for current use and 0.72 (95% CI: 0.35-1.47) for former use. The OR was not significantly different from unity for duration of use, age at starting use, indication (analgesia or cardiovascular prevention), and in women aged

Original languageEnglish
Pages (from-to)1171-1173
Number of pages3
JournalAnnals of Oncology
Issue number9
Publication statusPublished - 2000


  • Aspirin
  • Inflammation
  • Ovarian neoplasms
  • Pharmacoepidemiology
  • Risk factors
  • Salicylates

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Aspirin and ovarian cancer: An italian case-control study'. Together they form a unique fingerprint.

Cite this